CytomX Therapeutics, Inc. has achieved a second clinical candidate nomination under its TCB collaboration with Astellas Pharma US, Inc., triggering a $5 million milestone payment to CytomX. CytomX and Astellas are collaborating on multiple conditionally activated TCB programs with CytomX eligible to receive additional future preclinical, clinical and commercial milestones. CytomX retains a cost share and co-commercialization option on a select number of targets.   CytomX is a clinical-stage, o...